The Special Purpose Acquisition Companies and Life Sciences teams advised Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) in the successful completion of its business combination with Humacyte. The resulting combined company, Humacyte, commenced trading of its shares of common stock and warrants on the Nasdaq Global Select Market® under the ticker symbols "HUMA" and “HUMAW,” respectively, on August 27, 2021. The business combination was approved by AHAC stockholders on August 24, 2021.
As a result of the business combination, the Humacyte has received gross proceeds of approximately $245 million, including a $175 million PIPE financing and $70 million of cash held in the former AHAC trust account. Participating PIPE investors included Fresenius Medical Care, OrbiMed, Monashee Investment Management, Alexandria Venture Investments, UBS O’Connor, Morgan Creek Capital, and a number of other health care focused funds.
Alpha Healthcare Acquisition Corp. is a special purpose acquisition company formed for the purpose of effecting a business combination with one or more businesses in the healthcare sector. AHAC was founded by Mr. Rajiv Shukla, who has two decades of buyouts, investments and operations experience in the healthcare industry.
The Goodwin team was led by Mike Patrone and Laurie Burlingame, with invaluable assistance from Jocelyn Arel and Tom Levato, and included Julie Tibbets, Alexandra Denniston, Roger Cohen, Suhrid Wadekar, Jennifer Fay, Jacqueline Klosek, Janet Andolina, Mordecai Morgan, Bryan Kultgen, William Newman and Steven Tjoe.For additional details on the closing, please read the press release.